OBJECTIVE: To determine and compare the long-term effects of prednisone and deflazacort on the functional status of children with Duchenne muscular dystrophy. DESIGN: A total of 49 boys with Duchenne muscular dystrophy, between the age of 12 and 15 yrs, who were observed over a 7-yr period were reviewed retrospectively. Eighteen had been treated with prednisone, 12 with deflazacort, and 19 had no drug treatment. All boys treated with steroids received medication for >2 yrs before losing their ambulation. Lower and upper limb motor functions, pulmonary function, prevalence of surgery for scoliosis, and side effects were compared. RESULTS: Boys in the steroid groups were significantly more functional and performed better on all tests than boys not treated (P < 0.05). There was no significant difference between the deflazacort- and prednisone-treated groups (P > 0.05). The number of boys having scoliosis surgery in treated groups was significantly less than nontreated boys (P < 0.05). The control group's pulmonary capacity was decreasing and significantly less than both prednisone- and deflazacort-treated boys. Both deflazacort and prednisone had beneficial effect on pulmonary function and scoliosis. Cataracts, hypertension, behavioral changes, excessive weight gain, and vertebral fracture were noted as serious side effects. CONCLUSIONS: Prednisone and deflazacort have a significant beneficial effect on slowing the disease progress. Their usage in Duchenne muscular dystrophy may prolong ambulation and upper limb function with similar potency. Both steroids also improve pulmonary function, in addition to delaying the need for spinal interventions, with similar therapeutic profiles.
OBJECTIVE: To determine and compare the long-term effects of prednisone and deflazacort on the functional status of children with Duchenne muscular dystrophy. DESIGN: A total of 49 boys with Duchenne muscular dystrophy, between the age of 12 and 15 yrs, who were observed over a 7-yr period were reviewed retrospectively. Eighteen had been treated with prednisone, 12 with deflazacort, and 19 had no drug treatment. All boys treated with steroids received medication for >2 yrs before losing their ambulation. Lower and upper limb motor functions, pulmonary function, prevalence of surgery for scoliosis, and side effects were compared. RESULTS:Boys in the steroid groups were significantly more functional and performed better on all tests than boys not treated (P < 0.05). There was no significant difference between the deflazacort- and prednisone-treated groups (P > 0.05). The number of boys having scoliosis surgery in treated groups was significantly less than nontreated boys (P < 0.05). The control group's pulmonary capacity was decreasing and significantly less than both prednisone- and deflazacort-treated boys. Both deflazacort and prednisone had beneficial effect on pulmonary function and scoliosis. Cataracts, hypertension, behavioral changes, excessive weight gain, and vertebral fracture were noted as serious side effects. CONCLUSIONS:Prednisone and deflazacort have a significant beneficial effect on slowing the disease progress. Their usage in Duchenne muscular dystrophy may prolong ambulation and upper limb function with similar potency. Both steroids also improve pulmonary function, in addition to delaying the need for spinal interventions, with similar therapeutic profiles.
Authors: Abhinandan Batra; Ann Harrington; Donovan J Lott; Rebecca Willcocks; Claudia R Senesac; William McGehee; Dandan Xu; Sunita Mathur; Michael J Daniels; William D Rooney; Sean C Forbes; William Triplett; Jasjit K Deol; Ishu Arpan; Roxanne Bendixen; Richard Finkel; Erika Finanger; Gihan Tennekoon; Barry Byrne; Barry Russman; H Lee Sweeney; Glenn Walter; Krista Vandenborne Journal: Am J Phys Med Rehabil Date: 2018-10 Impact factor: 2.159
Authors: Panteleimon D Mavroudis; John van den Anker; Laurie S Conklin; Jesse M Damsker; Eric P Hoffman; Kanneboyina Nagaraju; Paula R Clemens; William J Jusko Journal: J Clin Pharmacol Date: 2019-02-11 Impact factor: 3.126
Authors: Kristin P Bibee; Ya-Jian Cheng; James K Ching; Jon N Marsh; Allison J Li; Richard M Keeling; Anne M Connolly; Paul T Golumbek; Jacob W Myerson; Grace Hu; Junjie Chen; William D Shannon; Gregory M Lanza; Conrad C Weihl; Samuel A Wickline Journal: FASEB J Date: 2014-02-05 Impact factor: 5.191
Authors: Donovan J Lott; Sean C Forbes; Sunita Mathur; Sean A Germain; Claudia R Senesac; H Lee Sweeney; Glenn A Walter; Krista Vandenborne Journal: Neuromuscul Disord Date: 2014-04-13 Impact factor: 4.296
Authors: Linda Pax Lowes; Lindsay Alfano; Laurence Viollet; Xiomara Quintero Rosales; Zarife Sahenk; Brian K Kaspar; K Reed Clark; Kevin M Flanigan; Jerry R Mendell; Michael P McDermott Journal: Muscle Nerve Date: 2012-02 Impact factor: 3.217
Authors: Mattia Quattrocelli; Isabella M Salamone; Patrick G Page; James L Warner; Alexis R Demonbreun; Elizabeth M McNally Journal: Am J Pathol Date: 2017-08-18 Impact factor: 4.307
Authors: Craig M McDonald; Erik K Henricson; R Ted Abresch; Jay J Han; Diana M Escolar; Julaine M Florence; Tina Duong; Adrienne Arrieta; Paula R Clemens; Eric P Hoffman; Avital Cnaan Journal: Muscle Nerve Date: 2013-05-16 Impact factor: 3.217